Status:
COMPLETED
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
Lead Sponsor:
GlaxoSmithKline
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
Detailed Description
Pazopanib has been formulated as an eye drop for the topical treatment of age-related macular degeneration (AMD). Safety, tolerability and pharmacokinetics have been evaluated in a first study conduct...
Eligibility Criteria
Inclusion
- Age-related macular degeneration patients diagnosed with subfoveal choroidal neovascularization in the study eye, with all of the following characteristics required:
- central subfield thickness \> 300 microns on investigator-determined OCT (inclusive of subretinal fluid)
- active subfoveal leakage as determined by investigator-determined fluorescein angiography
- minimally classic or occult with no classic CNV lesion
- lesion size no greater than 12 disc areas
- CNV \> 50% of lesion area
- \< 50% of lesion area with blood
- = 25% of lesion area with fibrosis
- Best-corrected ETDRS visual acuity in the study eye between 80 to 24 letters inclusive (approximately 20/25 and 20/320 or 4/5 to 4/63) at screening
- Female subjects must be of non-childbearing potential.
Exclusion
- Additional eye disease in the study eye that could compromise best corrected visual acuity (i.e. glaucoma with documented visual field loss, clinically significant diabetic retinopathy, ischemic optic neuropathy, or retinitis pigmentosa).
- CNV in the study eye due to other causes unrelated to age-related macular degeneration.
- The presence of retinal angiomatous proliferation (RAP) in the study eye, as determined by the investigator (confirmation by indocyanine green angiography is not required).
- Geographic atrophy involving the center of the fovea in the study eye.
- Anterior segment and vitreous abnormalities in the study eye that would preclude adequate observation of the fundus for photographs, fluorescein angiography and OCT.
- Vitreous, subretinal or retinal hemorrhage in the study eye that is unrelated to AMD.
- More than one prior photodynamic therapy (PDT) treatment in the study eye.
- PDT treatment in the study eye \< 12 weeks prior to dosing.
- Previous treatment in the study eye with ranibizumab (Lucentis) or bevacizumab (Avastin) without resolution of exudation (intraretinal and subretinal fluid as documented by OCT).
- Use of any treatment, either approved or experimental, for AMD in the study eye within 60 days of first dose of investigational product.
- Intraocular surgery in the study eye within 3 months of dosing.
- Aphakia or total absence of the posterior capsule (Yttrium aluminum garnet (YAG) capsulotomy permitted) in the study eye.
- History of vitrectomy in the study eye.
- Use of topical ocular medications in the study eye within 7 days of first dose of investigational product or expected use of topical ocular medications during the treatment period, with the exception of artificial tears (refer to Section 9.1)
- Active treatment in the fellow eye, with the exception of preservative-free artificial tears.
- Current use of medications known to be toxic to the retina, lens or optic nerve (e.g. desferoximine, chloroquine/hydrochloroquine, chlorpromazine, phenothiazines, tamoxifen, nicotinic acid, and ethambutol).
- Use of systemic steroids (\>10 mg prednisone or equivalent/day) within 14 days of first dose.
- An unwillingness to refrain from wearing contact lenses starting from the screening visit, through the follow-up visit
- Medical history or condition:
- Uncontrolled Diabetes Mellitus, with hemoglobin A1c (HbA1c) \> 10%.
- Myocardial infarction or stroke within 12 months of screening.
- Active bleeding disorder.
- Major surgery within 1 month of screening.
- Hepatic impairment.
- Uncontrolled hypertension
Key Trial Info
Start Date :
March 5 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 17 2009
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00612456
Start Date
March 5 2008
End Date
June 17 2009
Last Update
November 20 2017
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Tucson, Arizona, United States, 85704
2
GSK Investigational Site
Beverly Hills, California, United States, 90211
3
GSK Investigational Site
Pasadena, California, United States, 91105
4
GSK Investigational Site
Sacramento, California, United States, 95841